微流控芯片 GradientScreen 可预测儿童急性淋巴细胞白血病对药物组合的反应
Lab-on-a-chip predicts which cancer treatments may work for pediatric acute lymphoblastic leukemia
Emory University、Children's Healthcare of Atlanta 与 Georgia Tech 团队在 Nature Biomedical Engineering 发表 GradientScreen 微流控芯片检测,用单份血液或骨髓样本评估儿童急性淋巴细胞白血病细胞对三药组合及各配比的敏感性。
在 17 份样本的回顾性研究中,该微流控芯片把三药组合的药敏测试压缩到单次实验,可作为基因组数据之外的功能性补充。
More than 120,000 people in the U.S. are living with acute lymphoblastic leukemia (ALL), and 6,000 new cases are diagnosed each year. Of those, more than 3,500 will be in children. Responsible for 75% of all pediatric leukemia diagnoses, ALL is a rapid-onset blood cancer, preventing the body from producing mature, infection-fighting white blood cells, sometimes within a matter of months.
ALL requires immediate treatment, often a combination of chemotherapy, targeted therapy, immunotherapy and bone marrow transplants—but clinicians today have no way of knowing how specific drug combinations and dosages will impact the patient, or whether the treatment will be successful.
Currently, treatment strategies incorporate some degree of personalization based on leukemia subtype and risk classification. Despite this, most patients ultimately receive similar treatment regimens.
While advances in genomic sequencing have raised the possibility of truly personalized therapy, new complementary functional assays are still necessary to test live cancer cells directly against treatments to see which interventions actually work. Two patients can have the same genetic mutation but have very different responses to targeted therapy.
Testing drug combinations at diagnosis
To address this, a team of scientists and clinicians at Emory University, Children's Healthcare of Atlanta and Georgia Tech developed a new technology to help clinicians identify how children will respond to any given ALL treatment at the time of diagnosis, rather than after standard chemotherapy has been administered, saving invaluable time. The study is published in the journal Nature Biomedical Engineering.
GradientScreen, a microfluidic assay or a "lab-on-a-chip," rapidly measures how a patient's leukemia cells respond to drug combinations from a single blood or bone marrow sample. By complementing genomic and related data with direct measurements of drug sensitivity, GradientScreen provides an additional layer of information that can guide treatment decisions.
Rather than testing each drug pair and dose ratio individually—which would be time-consuming and resource-intensive—the assay uses microfluidic technology to evaluate the full range of combination ratios within a three-drug regimen in a single experiment.
"One of the holy grails in oncology is the ability to identify which patient is likely to be unresponsive to standard treatment before initiation of therapy begins, and to personalize which combination of standard chemotherapies with newer targeted or biological agents would be most beneficial, and at which dosages, for that particular person," says Wilbur Lam, M.D., Ph.D., professor of pediatrics and biomedical engineering at Emory University and Georgia Tech and principal investigator on the study.
"This is a significant advancement in helping pediatric oncologists nationwide understand which drugs to administer to patients who are most likely to resist standard chemotherapy," adds Lam, also a pediatric oncologist at Children's Healthcare of Atlanta. In fact, roughly 50% of the adult ALL population will experience relapse or refractory disease, in which the cancer doesn't respond to or proliferates during the intervention, and in the pediatric population, roughly 15% experience relapse.
Response patterns track treatment outcomes
Developed in Atlanta by Kendall Williams, Ph.D., and Dan Zhang, Ph.D., graduates of Emory University and Georgia Tech's biomedical engineering and bioengineering programs, respectively, GradientScreen works by exposing leukemia cells to three-drug combinations and measuring how many cancer cells survive.
By comparing how cells respond to single drugs versus combinations, the assay can identify which drug combinations and ratios work better together. This results in detailed "response patterns" that reflect how a patient's type of leukemia might react to treatment.
In this retrospective study of 17 leukemia cell and bone marrow samples of ALL patients, provided by The Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta, results using this platform correlated with patient treatment outcomes, including the amount of residual disease after induction treatment, which is the first month of chemotherapy, as well as whether the patient relapsed.
Expanding access and leukemia testing
"GradientScreen aims to improve as well as broaden access to precision medicine in leukemia treatment by helping clinicians identify harder-to-treat patients earlier in disease progression, and more precisely matching them with new, alternative treatment approaches," says Williams.
Initial next steps for the team include expansion to other leukemia types, including acute myeloid leukemia, to adult as well as pediatric patients.
Publication details
E. Kendall Williams et al., Gradient-driven microfluidic framework for the screening of ratiometric drug combinations towards precision oncology in paediatric leukaemia, Nature Biomedical Engineering (2026). DOI: 10.1038/s41551-026-01818-0
Journal information: Nature Biomedical Engineering
Clinical categories
Who's behind this story?
Sadie Harley
BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: Lab-on-a-chip predicts which cancer treatments may work for pediatric acute lymphoblastic leukemia (2026, October 28) retrieved 28 October 2026 from https://medicalxpress.com/news/2026-10-lab-chip-cancer-treatments-pediatric.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com